1. Clinical & Scientific Overview
Oseltamivir Phosphate (TIP-MED-000163, Reference Code [8.35]) is classified under
Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08) as a Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.35], p. 110): Fluvir (Hetero), Antiflu (Cipla), Tamiflu (Roche), Natflu (Natco) — Strengths & Dosage Forms: Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
3. Mechanism of Action & Pharmacodynamics
Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08): clinical efficacy is mediated via Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM 2022) for Treatment and post-exposure prophylaxis of Influenza A (including H1N1 / H3N2 strains) and Influenza B in high-risk outpatients (age >=65 yr, pregnancy, asthma/COPD, diabetes, heart/renal disease) and all hospitalised influenza patients.
4. Therapeutic Indications & Evidence-Supported Uses
- Treatment and post-exposure prophylaxis of Influenza A (including H1N1 / H3N2 strains) and Influenza B in high-risk outpatients (age >=65 yr, pregnancy, asthma/COPD, diabetes, heart/renal disease) and all hospitalised influenza patients
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Treatment (Adults & >=40 kg): 75 mg PO TWICE DAILY (q12h) for 5 DAYS. Paediatric Weight-Based Treatment (BD x 5d): <=15 kg: 30 mg BD; >15–23 kg: 45 mg BD; >23–40 kg: 60 mg BD; >40 kg: 75 mg BD. Prophylaxis: 75 mg PO ONCE DAILY for 10 days
Administration & Meal Timing: Initiate as early as possible (ideally within 48 hours of symptom onset, though hospitalised/pregnant/severe H1N1 patients benefit even when started >48h after onset!). Take WITH food or milk to reduce nausea! | Morning & Evening (12-hourly BD for Treatment; Once Daily for Prophylaxis)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!
Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!
Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!
7. Contraindications, Precautions & High-Risk Warnings
- REGULATORY UPDATE: Moved by MoHFW notification G.S.R. 292(E) from Schedule X to Schedule H1 (requires valid RMP prescription and 3-year Schedule H1 register entry!). Safe and strongly recommended across ALL trimesters of pregnancy!
Key Clinical Precautions: Renal (CrCl — active carboxylate is >90% renally excreted!): CrCl >60 mL/min: 75 mg BD; CrCl 31–60 mL/min: Reduce Treatment to 30 mg BD (Prophylaxis: 30 mg OD); CrCl 11–30 mL/min: Reduce Treatment to 30 mg ONCE DAILY; Haemodialysis: 30 mg after each HD session!
8. Adverse Effects Profile
- Nausea and vomiting (10–15% — markedly reduced by taking with food), headache, abdominal pain
- Rare neuropsychiatric events (delirium, hallucinations, abnormal behaviour — primarily in children/adolescents with influenza!), SJS/TEN, anaphylaxis
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Avoid Live Attenuated Influenza Vaccine (LAIV nasal spray) within 2 weeks before or 48 hours after Oseltamivir (Inactivated Injectable Flu Vaccine can be given at any time!)
- Minimal CYP450 interactions
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Start within 48 hours of flu fever/cough; take with food to prevent nausea; safe and life-saving during pregnancy; adjust to 30 mg capsule in kidney disease; seek emergency care if breathlessness or SpO2 <94% develops
- Meal & Clock Timing Instruction: Initiate as early as possible (ideally within 48 hours of symptom onset, though hospitalised/pregnant/severe H1N1 patients benefit even when started >48h after onset!). Take WITH food or milk to reduce nausea! (Morning & Evening (12-hourly BD for Treatment; Once Daily for Prophylaxis))
- Missed Dose Protocol: Take as soon as remembered unless within 2 hours of next dose; complete the full 5-day course
- Geriatric Dispensing Pearl: Always check CrCl in older adults — if CrCl is 31–60 mL/min, dispense the 30 mg capsule BD (not 75 mg BD!)
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Capsules: 30 mg, 45 mg, 75 mg; Oral Suspension Powder: 12 mg/mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.35] (p. 110)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.36]-C78 Entecavir — Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integras
- [8.36]-C79 Tenofovir + Lamivudine + Dolutegravir (TLD ART FDC) — Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integras
- [8.14] Acyclovir (Aciclovir) (and Valacyclovir comparison) — Synthetic Purine Nucleoside Analogue Antiviral (Activated by Vira
- [8.36] Tenofovir Disoproxil Fumarate (TDF), Entecavir & Dolutegravir-Based ART (TLD) — Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integras